Clinical trials: Muscle Hypotrophy
Hypogonadism, Diabetes
Effects of Aromatase Inhibition Versus Testosterone in Older Men With Low Testosterone: Randomized-Controlled Trial.
Background: Men≥65 years often produce lower levels of testosterone, meaning there is less testosterone circulating to the tissues of the body.
- Conditions
- Hypogonadism, Diabetes, Sarcopenia, Osteoporosis
- Trial name
- NCT00104572
- Testing
- Androgel (Testosterone Gel), Anastrozole (Aromatase Inhibitor), Calcium Cardone 500mg with vitamin D 400 IU
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- National Institute on Aging (NIA)
Muscle Loss
Enhanced Bioscaffold for Volumetric Muscle Loss
This is a prospective, single center study conducted at the University of Pittsburgh designed to test the applicability and utility of XenMatrix™ AB Surgical Graft in the restoration of function in the setting of volumetric…
- Trial name
- MTEC-VML (NCT04051242)
- Testing
- XenMatrix™ AB Surgical Graft
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- J. Peter Rubin, MD
Spinal Cord Injuries, Tetraplegia
Study Testing Benefits of Ursolic Acid (UA) as a Countermeasure To Myopenia and Insulin Resistance in Chronic Spinal Cord Injury (SCI)
This study will evaluate if Ursolic Acid supplementation may be effective in reducing muscle loss and improving blood sugar control in the SCI community.
- Conditions
- Spinal Cord Injuries, Tetraplegia, Paraplegia, Muscle Loss
- Trial name
- NCT05776862
- Testing
- Ursolic Acid, Strength Training
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Miami
Frailty
Enhancing Functional Capacity in Older Adults With Short Session High Intensity Interval Training
Frailty is a clinical condition of poor physiological reserve that increases risks for adverse health outcomes including falls, hospitalization and mortality.
- Trial name
- HIIT-VA (NCT03750006)
- Testing
- Short session HIIT
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Sporadic Inclusion Body Myositis
An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203
This extension study will provide data to further evaluate the efficacy, safety, and tolerability of three doses of BYM338 and to assess the long-term effects of BYM338 in patients with sporadic inclusion body myositis.
- Trial name
- NCT02573467
- Testing
- Bimagrumab
- Where
- 38 sites in United States, Australia and 8 more
- Volunteers
- 211 people
- Sponsor
- Novartis Pharmaceuticals
Activities of Daily Living, Accidental Fall
Bingocize: A Novel Mobile Application for Older Adult Health
This study tests the effectiveness of using a new mobile application (Bingocize®) to improve older adults' (a) adherence to an engaging exercise program, and (b) aspects of functional performance, health knowledge, dietary…
- Conditions
- Activities of Daily Living, Accidental Fall, Sarcopenia, Arteriosclerosis
- Trial name
- Bingocize (NCT03629912)
- Testing
- Socially-Based Exercise Intervention for Older Adults
- Where
- 4 sites in United States
- Volunteers
- 241 people, healthy volunteers welcome
- Sponsor
- Western Kentucky University
Sarcopenia
Dose Range Finding Study of Bimagrumab in Sarcopenia
The purpose of this study was to determine the efficacy of repeat dosing with multiple dose levels of bimagrumab on patient physical function, skeletal muscle mass and strength in older adults with sarcopenia.
- Trial name
- NCT02333331
- Testing
- bimagrumab
- Where
- 58 sites in United States, Australia and 11 more
- Volunteers
- 217 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Spinal Muscular Atrophy
Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA)
This was a Phase III multi-center, single dose (1.2 x 10^14 vector genomes), randomized, sham controlled, double-blind study that investigates the efficacy, safety and tolerability of OAV101B in treatment naive, sitting and never…
- Trial name
- STEER (NCT05089656)
- Testing
- OAV101
- Where
- 42 sites in United States, Brazil and 11 more
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals